Literature DB >> 14732819

Iron requirements in hemodialysis.

John A Sargent1, Sergio R Acchiardo.   

Abstract

The correction of anemia in dialysis patients with erythropoietin (EPO) can be frustrated by insufficient iron. To address this effect, we preloaded candidate EPO patients with intravenous iron in the early 1990s. Preloading with 900-1,525 mg of iron yielded the following results: 70% of patients had increasing hematocrits (HCTs) without EPO, and 40% of patients had HCTs greater than 30%. Apparent lack of iron led to blood loss studies. Routes evaluated were blood sampling, dialyzer clotting, blood in the dialyzer circuit and postdialysis bleeding. Projected annual losses were between 2,516 and 5,126 ml, depending on circuit and posttreatment losses. In terms of red cell loss, the results are comparable to those in the early days of dialysis before the introduction of current technology. Extension of these studies to daily dialysis predicts possible losses with this 6 times a week therapy of between 4,663 and 9,884 ml per year. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14732819     DOI: 10.1159/000074931

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  25 in total

1.  Ferric citrate controls phosphorus and delivers iron in patients on dialysis.

Authors:  Julia B Lewis; Mohammed Sika; Mark J Koury; Peale Chuang; Gerald Schulman; Mark T Smith; Frederick C Whittier; Douglas R Linfert; Claude M Galphin; Balaji P Athreya; A Kaldun Kaldun Nossuli; Ingrid J Chang; Samuel S Blumenthal; John Manley; Steven Zeig; Kotagal S Kant; Juan Jose Olivero; Tom Greene; Jamie P Dwyer
Journal:  J Am Soc Nephrol       Date:  2014-07-24       Impact factor: 10.121

2.  Application of Reticulocyte-Based Estimation of Red Blood Cell Lifespan in Anemia Management of End-Stage Renal Disease Patients.

Authors:  Ly Minh Nguyen; Calvin J Meaney; Gauri G Rao; Mandip Panesar; Wojciech Krzyzanski
Journal:  AAPS J       Date:  2020-02-03       Impact factor: 4.009

3.  Rest Easy with Intravenous Iron for Dialysis Patients? High Dose IV Iron Safety.

Authors:  Xiaojuan Li; Abhijit V Kshirsagar
Journal:  Clin J Am Soc Nephrol       Date:  2018-02-20       Impact factor: 8.237

4.  Testing two (of several) intravenous iron dosing strategies in hemodialysis.

Authors:  Margaret K Yu; Glenn M Chertow
Journal:  Ann Transl Med       Date:  2019-07

5.  Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD.

Authors:  Kausik Umanath; Diana I Jalal; Barbara A Greco; Ebele M Umeukeje; Efrain Reisin; John Manley; Steven Zeig; Dana G Negoi; Anand N Hiremath; Samuel S Blumenthal; Mohammed Sika; Robert Niecestro; Mark J Koury; Khe-Ni Ma; Tom Greene; Julia B Lewis; Jamie P Dwyer
Journal:  J Am Soc Nephrol       Date:  2015-03-03       Impact factor: 10.121

Review 6.  Markers of iron status in chronic kidney disease.

Authors:  Adam E Gaweda
Journal:  Hemodial Int       Date:  2017-03-22       Impact factor: 1.812

7.  Reticulocyte-based estimation of red blood cell lifespan.

Authors:  Wojciech Krzyzanski; Michael E Brier; Timothy M Creed; Adam E Gaweda
Journal:  Exp Hematol       Date:  2013-05-24       Impact factor: 3.084

8.  Intravenous iron exposure and mortality in patients on hemodialysis.

Authors:  Dana C Miskulin; Navdeep Tangri; Karen Bandeen-Roche; Jing Zhou; Aidan McDermott; Klemens B Meyer; Patti L Ephraim; Wieneke M Michels; Bernard G Jaar; Deidra C Crews; Julia J Scialla; Stephen M Sozio; Tariq Shafi; Albert W Wu; Courtney Cook; L Ebony Boulware
Journal:  Clin J Am Soc Nephrol       Date:  2014-10-15       Impact factor: 8.237

9.  Impact of frequent hemodialysis on anemia management: results from the Frequent Hemodialysis Network (FHN) Trials.

Authors:  Daniel B Ornt; Brett Larive; Anjay Rastogi; Mohamad Rashid; John T Daugirdas; Ann Hernandez; Manjula Kurella Tamura; Rita S Suri; Nathan W Levin; Alan S Kliger
Journal:  Nephrol Dial Transplant       Date:  2013-01-27       Impact factor: 5.992

Review 10.  Anaemia in kidney disease: harnessing hypoxia responses for therapy.

Authors:  Mark J Koury; Volker H Haase
Journal:  Nat Rev Nephrol       Date:  2015-06-09       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.